News

Merck's Verona Acquisition: Plugging A $4B Hole In A $20B Gap
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
Verona Pharma plc (VRNA): Jim Cramer Approves The Merck Acquisition
We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Verona Pharma plc (NASDAQ:VRNA) ...
MedCity News4d
Merck Breathes Life Into Its Respiratory Prospects With $10B Deal to ...
Merck has reached a $10 billion deal to acquire Verona Pharma, a biotech whose first-in-class drug is already commercialized in one prevalent lung disorder and is showing promise in other ...
BioPharma Dive2d
With Verona deal, Merck wagers on strength of lung drug’s patents
The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...
Piper Sandler Lifts PT on Verona Pharma (VRNA) Stock, Maintains Overweight
Verona Pharma plc (NASDAQ:VRNA) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. Piper ...
Raleigh pharma's $10B sale pays off for Boston, NY investment firms
Investment firms in Boston and New York could see the biggest gains from the sale of a Raleigh drugmaker. Raleigh firm rides ...
These Stocks Are Moving the Most Today: Nvidia, AES, Verona Pharma, WPP, Bloom Energy, Aehr Test Systems, and More
Stocks traded higher Wednesday as Wall Street focused on the latest tariff developments from President Donald Trump and ...
Merck Acquires Verona Pharma for $10B to Support Portfolio with COPD Drug Ohtuvayre Ahead of Keytruda Patent Expiration
Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition ...